{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:18Z","timestamp":1792979898822,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National Cancer Research and Development Fund","award":["2023-A-16"],"award-info":[{"award-number":["2023-A-16"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12185-025-03942-0","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T04:31:48Z","timestamp":1739161908000},"page":"462-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Concomitant letermovir affects the optimal concentration-to-dose ratio of tacrolimus after switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving fluconazole prophylaxis"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-2502","authenticated-orcid":false,"given":"Toshihisa","family":"Nakashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"3942_CR1","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","volume":"113","author":"M Boeckh","year":"2009","unstructured":"Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711\u20139.","journal-title":"Blood"},{"key":"3942_CR2","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433\u201344.","journal-title":"N Engl J Med"},{"key":"3942_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40265-017-0860-8","volume":"78","author":"ES Kim","year":"2018","unstructured":"Kim ES. Letermovir: first global approval. Drugs. 2018;78:147\u201352.","journal-title":"Drugs"},{"key":"3942_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/cpt.1120","volume":"105","author":"YH Wang","year":"2019","unstructured":"Wang YH, Chen D, Hartmann G, Cho CR, Menzel K. PBPK modeling strategy for predicting complex drug interactions of letermovir as a perpetrator in support of product labeling. Clin Pharmacol Ther. 2019;105:515\u201323.","journal-title":"Clin Pharmacol Ther"},{"key":"3942_CR5","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12185-021-03105-x","volume":"113","author":"T Nakashima","year":"2021","unstructured":"Nakashima T, Inamoto Y, Fukushi Y, Doke Y, Hashimoto H, Fukuda T, et al. Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation. Int J Hematol. 2021;113:872\u20136.","journal-title":"Int J Hematol"},{"key":"3942_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12185-016-2135-7","volume":"105","author":"K Suetsugu","year":"2017","unstructured":"Suetsugu K, Ikesue H, Miyamoto T, Shiratsuchi M, Yamamoto-Taguchi N, Tsuchiya Y, et al. Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2017;105:361\u20138.","journal-title":"Int J Hematol"},{"key":"3942_CR7","unstructured":"Guidelines on TDM of immunosuppressive drugs in organ transplantation. Kanehara Publishing Ltd: Japan. 2014; 1st edn: p 31"},{"key":"3942_CR8","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664\u201371.","journal-title":"Blood"},{"key":"3942_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3942_CR10","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1592\/phco.26.12.1730","volume":"26","author":"AH Saad","year":"2006","unstructured":"Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730\u201344.","journal-title":"Pharmacotherapy"},{"key":"3942_CR11","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1097\/00007890-199604270-00026","volume":"61","author":"CL Osowski","year":"1996","unstructured":"Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation. 1996;61:1268\u201372.","journal-title":"Transplantation"},{"key":"3942_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0009-9236(97)90150-8","volume":"62","author":"LC Floren","year":"1997","unstructured":"Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther. 1997;62:41\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"3942_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12185-021-03277-6","volume":"115","author":"T Nakashima","year":"2022","unstructured":"Nakashima T, Inamoto Y, Aoki J, Ito A, Tanaka T, Kim SW, et al. Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal. Int J Hematol. 2022;115:158\u201362.","journal-title":"Int J Hematol"},{"issue":"56","key":"3942_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1046\/j.1365-2133.1999.00011.x","volume":"141","author":"HI Katz","year":"1999","unstructured":"Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol. 1999;141(56):26\u201332.","journal-title":"Br J Dermatol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03942-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T09:17:53Z","timestamp":1742375873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03942-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3942"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03942-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest. YI is a lead reviewer of the International Journal of Hematology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}